The futures are trading flat on Wednesday after a second strong day for Wall Street, as the Dow Jones Industrial Average hit ...

In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 in the US, EU, Canada, and Australia for adults aged 50 and older, ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey ...

Moderna is up 20% YTD, with a golden cross suggesting a trend reversal. Momentum indicators make it a top 2026 pick.

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...

This stock is a great choice for cautious and aggressive investors.

Bayer's Monsanto has sued Pfizer, BioNTech and Moderna for allegedly misusing its messenger RNA technology in COVID vaccines.

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

Stéphane Bancel, CEO of vaccine maker Moderna, addressed shareholders in a letter that dissected the events of 2025 while projecting a positive outlook for the company’s future in 2026 and beyond.

German agrichemical giant Bayer confirmed to AFP today that it was suing American pharmaceutical firms Pfizer, Moderna and ...

An update from Moderna ( ($MRNA) ) is now available. In a January 5, 2026 letter to shareholders, Moderna reviewed a challenging 2025 operating ...